Reading CORT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CORT free→Reading CORT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CORT free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral. Earnings quality is robust, and management's track record is stable. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, CORT trades below typical levels. Peer multiples imply a price about 447% below where it trades (it looks expensive on this basis); the read is rich. This analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 3 valuation methods, at three horizons. Current price $83.71. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $84, CORT's earnings are too small for P/E to mean much; on sales it trades at 12× p/s (5.3× the 2× p/s peer median, and 1.3× even its own history). At a normal multiple the price implies ~447% near-term growth vs our ~14% forecast. That gap is an optionality premium a financial-multiple model can't price — our $16 fair value covers only the as-is business, low confidence. Analysts: $67–$135. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 447% near-term growth, well above our forecast of about 14%. This describes what's priced in, not a forecast of the move.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 2.54x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity.
4 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.05 → $0.04 (-29.4% / 30d). 1 raised, 2 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 83% of analysts rate Buy.
2 PT revisions / 30d. Avg target 68.7% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$143.
How much price usually moves either way.
On a bad day, this stock has moved -$471.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,440.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The outcome of the lawsuit could impact the company's reputation and finances. Investors are paying close attention.
Confirms:The DOJ declines to pursue further action, clearing the company.
Disproves:The DOJ takes more action against the company, which could lead to penalties.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Advances: Increase 2026 revenue guidance
Positive trial data supports revenue growth expectations.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On May 19, 2026, Corcept Therapeutics Incorporated (the “Company”) learned that the United States Department of Justice (the “DOJ”) had filed a Notice of Election to Decline Intervention (the “Notice”) in a civil qui tam action filed against the company, captioned U.S. et al. ex rel. Stephen Elliott v. Corcept Therapeutics, Inc. , No. 17-CV-1303 (SRC) (D.N.J.). That action was initiated in February 2017, in the District Court of New Jersey, by a former employee of the Company (t…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$67.00 – $135.00 (median $81.50) · 6 analysts · as of 2026-06-02
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CORT Corcept Therapeutics Incorporated | Below typical Show detailsSector percentile: 12 of 100 | expensive | elevated |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 89 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 75 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 68 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 64 of 100 | fair | low |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to increase the 2026 revenue guidance to between $950 million and $1,050 million.
Management is focusing on improving operational efficiency to enhance profitability.
Why it matters: The FDA's decision will affect Corcept's product range and how much money it makes.
Confirms:The FDA approved the NDA for relacorilant in Cushing's syndrome. This happened before the PDUFA date of July 11, 2026.
Disproves:The FDA denies the NDA for relacorilant in Cushing's syndrome or asks for more data.
Why it matters: Changes to the incentive plan can affect how motivated management is. This can also impact how well the company performs.
Confirms one read:Announcement of new performance metrics tied to the incentive plan.
Confirms the other:No changes or updates to the incentive plan metrics.
Why it matters: The case outcome could affect Corcept's reputation and financial health.
Confirms:No further legal actions or negative developments arise from the DOJ case.
Disproves:New legal issues or bad findings come from the DOJ case affecting the company.
Why it matters: Earnings results will show how well Corcept is performing. This could affect investor confidence.
Confirms one read:Earnings report shows revenue growth above 10% year over year.
Confirms the other:Earnings report shows revenue growth below 5% year over year.
Why it matters: A slowdown in sector growth could impact Corcept's performance. It signals broader challenges.
Confirms:Sector revenue growth falls below its median of 10%.
Disproves:Sector revenue growth remains above its median.
Why it matters: An update could signal whether the company is on track to meet its revenue goals for the year.
Confirms:Management raised the 2026 revenue guidance to over $1,050 million. This was announced during the Q2 earnings call.
Disproves:Management lowered the 2026 revenue guidance to below $950 million. This was announced during the Q2 earnings call.
Advances: Increase 2026 revenue guidance
Positive trial data supports revenue growth expectations.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 21, 2026, Corcept Therapeutics Incorporated (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the Amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan (the “Amended 2024 Plan”) to increase the number of shares available there…
Results of Operations and Financial Condition.
Results of Operations and Financial Condition.
Termination of a Material Definitive Agreement. On October 10, 2025, Corcept Therapeutics Incorporated (the “Company”) delivered to Optime Care, Inc. (“Optime”) a notice of termination of that certain Distribution Services Agreement, dated August 4, 2017, as amended and restated on April 1, 2024, by and between Optime and the Company (the “Agreement”), effective as of January 8, 2026. As previously disclosed, under the terms of the Agreement, Optime has acted as a specialty pharmacy distribut…